Four phase III trials with gefitinib or erlotinib in patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC have demonstrated higher response rates and longer progression-free survival (PFS) times than those of patients who received platinum doublets as first-line chemotherapy (5–8). Here, EGFR is linked to non-small cell lung carcinoma.